Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 5, 2017 – The European Commission (EC) has approved pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy. The frontline approval for cisplatin-ineligible patients was based on the phase II KEYNOTE-052 trial, in which the overall response rate (ORR) was 29% (95% CI, 25-34), with … (leggi tutto)